MeSH D000795 - fabry disease
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Amicus Therapeutics | Migalastat | Galafold | 2027-05-16 | 2018-08-10 | ||
| Chiesi Farmaceutici | Pegunigalsidase alfa | Elfabrio | 2023-05-09 | |||
| Sanofi | Agalsidase beta | Fabrazyme | 2003-04-24 | |||
| Takeda | Agalsidase alfa | Replagal | 2001-08-03 |
Clinical Trials
Historical Success Rate
Phase 1
88%7/8
Phase 2
60%6/10
Phase 3
73%8/11
Approved: 5Overall Success rate: 38%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use